• About us
• Contact

Advertisement

Person › Details

Mark Alles (Celgene Corporation (Nasdaq: CELG))

Alles, Mark (Celgene 201306 EVP + Global Head Hematology + Oncology)

 

	Organisation	Celgene Corporation (Nasdaq: CELG)
	Group	Bristol Myers Squibb (BMS) (Group)
	Product	cancer drug

Record changed: 2024-05-02

Advertisement

More documents for Mark Alles

• [1] TORL BioTherapeutics, LLC. (4/10/24). "Press Release: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline". Los Angeles, CA....
• [2] Bristol-Myers Squibb Company. (1/3/19). "Press Release: Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company". New York, NY & Summit, NJ....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.